These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1433799)

  • 21. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
    Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
    Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
    Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute hypokalemic tetraparesis induced by intravenous methotrexate.
    Thuss-Patience PC; Peters U; Jurkat-Rott K; Pink D; Kretzschmar A; Dörken B; Reichardt P
    J Clin Oncol; 2003 May; 21(9):1896-7. PubMed ID: 12721279
    [No Abstract]   [Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.
    Bacci G; Picci P; Ferrari S; Sangiorgi L; Mercuri M; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Comandone A
    Chir Organi Mov; 1995; 80(1):1-10. PubMed ID: 7641534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.
    Rosen G; Nirenberg A
    Cancer Treat Rep; 1982 Sep; 66(9):1687-97. PubMed ID: 6981454
    [No Abstract]   [Full Text] [Related]  

  • 27. Sarcoidosis following adjuvant high-dose methotrexate therapy for osteosarcoma.
    Sybert A; Butler TP
    Arch Intern Med; 1978 Mar; 138(3):488-9. PubMed ID: 272865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
    Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
    Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
    Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
    Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions.
    Broxson EH; Stork LC; Allen RH; Stabler SP; Kolhouse JF
    Cancer Res; 1989 Nov; 49(21):5879-83. PubMed ID: 2790801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics of low-dose methotrexate therapy in rheumatoid diseases].
    Weber MH
    Internist (Berl); 1993 Sep; 34(9):866-70. PubMed ID: 8407205
    [No Abstract]   [Full Text] [Related]  

  • 33. High dose systemic methotrexate-associated acute neurologic dysfunction.
    Packer RJ; Grossman RI; Belasco JB
    Med Pediatr Oncol; 1983; 11(3):159-61. PubMed ID: 6602269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
    Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
    Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
    Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
    Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma].
    Ridolfi L; Barisone E; Vivalda M; Vivenza C; Brach Del Prever A; Leone L; Miniero R
    Minerva Pediatr; 1996 May; 48(5):193-200. PubMed ID: 8926955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
    Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Severe renal impairment of methotrexate elimination after high dose therapy].
    Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
    Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
    Piekarczyk A; Zimak J; Taljański W
    Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.